Efficacy of Low Dose Combined Cyclophosphamide and Tacrolimus Induc-tion in the Treatment of Lupus Nephritis
Objective To explore the efficacy of low dose combined cyclophosphamide and tacrolimus in inducing re-mission of lupus nephritis and the effect on peripheral blood T lymphocytes.Methods A total of 60 patients with lu-pus nephritis(LN)admitted to the Rheumatology and Immunology and Nephrology Department of Xinyi People's Hos-pital from May 2018 to August 2022 were selected as the study objects and divided into two groups according to ran-dom number table method,with 30 patients in each group.Patients in both groups received conventional basic treat-ment such as glucocorticoids and hydroxychloroquine sulfate tablets.The control group received low-dose cyclophos-phamide intravenous impact therapy,and the study group received low-dose tachlimus on the basis of the control group.After 6 months of treatment,the clinical efficacy,peripheral blood T lymphocyte subsets and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 93.33%,which was significantly higher than that of the control group(73.33%),and the difference was statistically sig-nificant(χ2=4.320,P<0.05).Erythrocyte sedimentation rate,24 h urinary protein quantity and peripheral blood creati-nine level of the study group were significantly lower than those of the control group,and the differences were statisti-cally significant(all P<0.05).The levels of peripheral blood CD3+,CD4+,CD4+/CD8+in the study group were higher than those in the control group,and the differences were statistically significant(all P<0.05).The level of CD8+in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions was 23.33%in the study group and 20.00%in the control group,and there was no sig-nificant difference between the two groups(χ2=0.098,P>0.05).Conclusion The combined cyclophosphamide and ta-crolimus with low dose has definite remission effect on lupus nephritis and high drug safety.
NETL
NSTL
万方数据
维普
